COVID-19
COALITION
About Featured Coalition Past Programs Updates

About

The MJH Life Sciences COVID-19 Coalition was formed in September 2020 to help keep health care professionals up-to-date on the science and latest information on COVID-19.

Featured Content

MJH



Meet the Coalition

MJH

Saskia V. Popescu, PhD, MPH, MA, CIC

Senior Infection Prevention Epidemiologist
Phoenix, Arizona

Full Bio
MJH

Angela Rasmussen, PhD

Associate Research Scientist
Columbia University Mailman School of Public Health

Full Bio
MJH

Tina Q. Tan, MD, FAAP, FIDSA, FPIDS

Professor of Pediatrics
Northwestern University Feinberg School of Medicine

Full Bio
MJH

Jason M. Pogue, PharmD, BCPS, BCIDP

Clinical Professor
University of Michigan College of Pharmacy

Full Bio
MJH

Margaret Liu, MD

CEO, PAX Therapeutics
Professor of Microbiology and Immunology
University of California, San Francisco

Full Bio
MJH

Paul E. Sax, MD

Clinical Director
Division of Infectious Diseases
Brigham and Women’s Hospital

Full Bio
MJH

Amesh Adalja, MD

Senior Scholar
Johns Hopkins Center for Health Security

Full Bio
MJH

Carlos del Rio, MD

Distinguished Professor of Medicine
Emory University School of Medicine

Full Bio
MJH

Rachna Kalia, MD

Clinical Assistant Professor
Psychiatry & Behavioral Sciences
KU School of Medicine-Wichita

Full Bio
MJH

Utibe R. Essien, MD, MPH

Assistant Professor of Medicine
University of Pittsburgh School of Medicine

Full Bio


Past Programs

MJH

Building Confidence in COVID-19 Vaccination: A Toolbox of Talks From Leaders in the Field

The development and rollout of vaccines to combat COVID-19 is an incredible feat of innovation by the scientific community, but vaccines can only work when they are administered, particularly to high-risk groups.

Vaccine hesitancy has swirled into a pandemic of its own, fueled by misinformation and mistrust. The scientific and research communities, coupled with health care professionals, are in a prime position to restore trust and confidence. However, we must first explore the root causes of vaccine hesitancy, from the psychology of decision-making and messaging to strategies for boosting vaccine confidence on the front lines and among at-risk populations.

Watch this webinar, co-hosted by the International Society for Vaccines and the MJH Life Sciences™ COVID-19 Coalition, to hear from the experts on key issues driving vaccine hesitancy and how scientists and health care professionals can combat that mindset.

MJH

Legal and Ethical Considerations of COVID-19 Vaccination

In an incredible feat of innovation, the pharmaceutical industry and scientific community developed, tested, and secured emergency use authorization (EUA) for two coronavirus disease 2019 (COVID-19) vaccine candidates in a period of nine months, with others close behind.

This medical breakthrough was beyond impressive but not a panacea for the pandemic. The rollout, distribution, and administration of COVID-19 vaccines are the next challenges we must conquer. With the rollout comes unanswered questions involving complex legal and ethical considerations. For example, is there a liability concern in potentially mandating a vaccine only available via EUA? How do we navigate the issue of exemptions or privacy concerns?

Watch the MJH Life Sciences COVID-19 Coalition webinar “Legal and Ethical Considerations of COVID-19 Vaccination,” for answers to these questions and more from our panel of experts in a discussion moderated by Amesh Adalja, MD.

MJH

Care for the Caregiver: Avoiding Burnout. Anxiety, and Stress on the COVID-19 Front Lines

The coronavirus disease 2019 (COVID-19) pandemic posed near-crippling challenges to our health care infrastructure and changed the way of life for people around the world. But it had an even bigger impact on the men and women on the frontlines &emdash; the health care providers who work around the clock, with little to no food or sleep, with limited personal protective equipment (PPE), fighting physical, mental, and emotional exhaustion — who witnessed firsthand the true tragedy a pandemic can inflict.

From PPE shortages and rationing of resources to battling anxiety, stress, and burnout, those on the frontlines have spent the better part of a year fighting the pandemic one patient at a time. But who cares for the caregiver?

Watch the MJH Life SciencesCOVID-19 Coalition webinar event, “Care for the Caregiver: Avoiding Burnout, Anxiety, and Stress on the COVID-19 Frontlines” for an important conversation about the challenges of working in health care during a pandemic, as well as some strategies to cope.

Takeaways From “Care for the Caregiver: Avoiding Burnout, Anxiety, and Stress on the COVID-19 Front Lines”

Health care workers around the world have faced unprecedented challenges during the past year, battling the global coronavirus disease 2019 (COVID-19) pandemic with limited resources and unlimited stress. The MJH Life Sciences COVID-19 Coalition discussed the pressure placed on medical professionals during the pandemic during a recent webinar titled “Care for the Caregiver: Avoiding Burnout, Anxiety, and Stress on the COVID-19 Front Lines.”

The coalition, a partnership with top health care thought leaders across a variety of medical disciplines, shared personal experiences with physical, cognitive, emotional, and system challenges; discussed success stories; and examined strategies for caring for the caregivers.

Click here to download our whitepaper.

MJH

Emerging SARS-CoV-2 Variants: What You Need to Know

B.1.351 in South Africa. B.1.1.7 in the United Kingdom. These emerging coronavirus variants, some billed as more contagious forms of SARS-CoV-2, have dominated reports as they popped up across the globe within the last couple months. Genetic mutation is anticipated, especially for RNA viruses as they multiply, but at what point should clinicians and the scientific community become concerned? With a novel pathogen like SARS-CoV-2, there are still many unknowns.

How did these variants emerge? Are they indeed more transmissible? Do they cause more serious disease? What does the scientific evidence support? What should the public response be? Will the developed vaccines provide coverage against these variants?

Watch the MJH Life Sciences COVID-19 Coalition webinar event “Emerging SARS-CoV-2 Variants: What You Need to Know” for an enlightened conversation with a panel of frontline thought leaders, including experts in virology, epidemiology, and immunology, hosted by Dr. Carlos del Rio.

8 Key Takeaways from “Emerging SARS-CoV-2 Variants: What You Need to Know”

Like all viruses, SARS-CoV-2 has been mutating as it spreads from person to person throughout the world during the coronavirus disease 2019 (COVID-19) pandemic. Some variants that have emerged recently are raising concerns about the possibility of increased transmissibility, along with questions about whether they will lead to more severe disease, whether current vaccines will provide protection against them, and how they might affect public health efforts.

During a recent webinar titled “Emerging SARS-CoV-2 Variants: What You Need to Know,” the MJH Life Sciences COVID-19 Coalition discussed emerging variants of SARS-CoV-2 that have appeared across the globe during the pandemic and what they mean for immunity and public health. The coalition is a partnership with top health care thought leaders across a variety of medical disciplines.

Click here to download our whitepaper.

MJH

Color and COVID-19: The Virus’ Disproportionate Impact

Coronavirus disease 2019 (COVID-19) not only exposed major gaps in our national pandemic response. It also revealed structural inequities that led to disproportionate impacts of the virus among racial and ethnic minority groups. According to data from APM Research Lab released in December 2020, 1 in 1,625 White Americans has died from COVID-19 compared with 1 in 1,275 Latino Americans, 1 in 925 Indigenous Americans, and 1 in 875 Black Americans. This is the result of a combination of discrimination and social factors that create racially inequitable impacts.

Watch our webinar “Color and COVID-19: The Virus’ Disproportionate Impact” for an enlightened conversation with a panel of frontline experts.

10 Key Takeaways from “Color and COVID-19: The Virus'” Disproportionate Impact

In the 10 months since the World Health Organization declared the coronavirus disease 2019 (COVID-19) a global pandemic, the disease has killed more than 400,000 Americans, taking a disproportionate toll on communities of color. COVID-19 has killed 1 in 595 Indigenous Americans, 1 in 735 Black Americans, 1 in 895 Pacific Islander Americans, 1 in 1,000 Latino Americans, and 1 in 1,030 White Americans. During a recent webinar titled “Color and COVID-19: The Virus’ Disproportionate Impact” hosted by the MJH Life Sciences™ COVID-19 Coalition, experts discussed how the virus has affected communities of color, vaccine distribution and uptake, and their visions for the future.

Click here to download our whitepaper.

MJH

Innovative Testing Strategies for COVID-19 Containment

Diagnostic vs. antibody. At-home vs. point-of-care collection. Sensitivity vs. specificity. There is a lot to consider when testing for past or present coronavirus disease 2019 (COVID-19) infection, such as when to test, how to test, and which test to use. We rely on testing to paint an accurate picture of disease prevalence, but what if there’s a better strategy than the current approach?

Watch our webinar “Innovative Testing Strategies for COVID-19 Containment” to hear straight from the experts on their proposals for effective testing tactics.

7 Key Takeaways from “Innovative Testing Strategies for COVID-19 Containment”

Testing is crucial to combating the coronavirus disease 2019 (COVID-19) pandemic. Along with identifying the infection in individuals seeking treatment, testing sheds light on the virus in the population and how to mitigate transmission. The MJH Life Sciences COVID-19 Coalition discussed the current state of COVID-19 testing and emerging testing strategies during “Innovative Testing Strategies for COVID-19 Containment,” the sixth in a series of webinars. The coalition is a partnership with top health care thought leaders across a variety of medical disciplines.

Click here to download our whitepaper.

MJH

Thinking Long-Term: COVID-19’s Clinical Consequences and Mental Health Effects

A novel disease. A global pandemic. A wide-ranging clinical spectrum. A new way of life. It’s unclear what impact coronavirus disease 2019 (COVID-19) will have in the long run in terms of health consequences for those who have been infected and “recovered.” Additionally, there are sure to be costs associated with adapting to our new virtual world, especially when it comes to the mental health of children and young adults.

Watch our webinar, “Thinking Long-Term: COVID-19’s Clinical Consequences and Mental Health Effects, to hear straight from the experts regarding existing data on COVID-19’s clinical course and potential long-term health consequences, as well as the pandemic’s effect on the mental health of children and young adults navigating a virtual lifestyle.

6 Key Takeaways from “Thinking Long-Term: COVID-19’s Clinical Consequences and Mental Health Effects”

Eleven months after the discovery of SARS-CoV-2, investigators continue to learn about the wide-ranging effects of the virus that is responsible for the coronavirus disease 2019 (COVID-19) pandemic.

The MJH Life Sciences COVID-19 Coalition discussed the long-term health complications of the disease along with the consequences of adapting to a world under pandemic restrictions during the fifth in a series of webinars, Thinking Long-Term: COVID-19’s Clinical Consequences and Mental Health Effects. The coalition is a partnership with top health care thought leaders across a variety of medical disciplines.

Click here to download our whitepaper.

MJH

Race for a Vaccine: The Latest Updates on COVID-19 Prevention

As investigators worldwide race to develop a safe and effective vaccine against coronavirus disease 2019 (COVID-19), other teams are working to explore additional means of prevention against the SARS-CoV-2 virus.

Phase 3 data from vaccine clinical trials are expected shortly, and public health officials are hard at work drafting plans for mass delivery and distribution once a vaccine candidate has cleared US Food and Drug Administration approval.

Meanwhile, antibody-based options for prophylaxis are also in development, including monoclonal antibodies.

Watch our Webinar, “Race for a Vaccine: The Latest Updates in COVID-19 Prevention,” to hear straight from the experts regarding the newest developments and clinical data on all things COVID-19 prevention, from vaccines to potential prophylaxis treatments.

Our panel features Larry Corey, MD, who heads the operations center for the COVID-19 Prevention Network, the national collaboration started by Dr. Anthony Fauci of the National Institute of Allergy and Infectious Diseases to manage the multiple large-scale clinical trials of vaccine candidates; in addition to Myron S. Cohen, MD, who is leading the monoclonal antibody arm of the COVID-19 Prevention Network.

Race for a Vaccine: The Latest Updates on COVID-19 Prevention

The MJH Life Sciences COVID-19 Coalition explored the latest developments in COVID-19 prevention efforts in the fourth of its biweekly series of webinars, “Race for a Vaccine: The Latest Updates in COVID-19 Prevention.” Along with vaccine candidates, the webinar addressed monoclonal antibodies.

Click here to download our whitepaper.

MJH

Navigating the COVID-19 Treatment Landscape: Clinical Controversies Explained

From antivirals and anti-inflammatory therapy to corticosteroids and convalescent plasma, the treatment landscape for coronavirus disease 2019 (COVID-19) evolves each and every day as more and more studies are added to the literature bank.

But what helps and what hurts? When should one treatment be used over another, and what considerations factor into those decisions? What do the data say? What’s in the pipeline?

Watch our webinar, “Navigating the COVID-19 Treatment Landscape,” and stay up to speed on all the current treatment agents in our arsenal, including when or in which patients to use each, as well as a review of the therapeutic pipeline. Our group of experts includes pharmacists who serve on treatment guidelines panels for both the National Institutes of Health and Infectious Diseases Society of America.

Five Takeaways from Navigating COVID-19 Treatment Landscape: Clinical Controversies Explained

The coronavirus disease 2019 (COVID-19) pandemic has changed the landscape for infectious disease treatments, with drug developers and investigators racing to identify, develop and test therapies for the disease caused by the SARS-CoV-2 virus. In the third of its biweekly series of webinars, the MJH Life Sciences™ COVID-19 Coalition, a partnership with top health care thought leaders across a variety of medical disciplines, addressed some of the considerations and controversies surrounding COVID-19 treatments.

Click here to download our whitepaper.

MJH

Fact or Fiction? COVID-19 Myths and Controversies

The SARS-CoV-2 virus is totally airborne. Children are immune to COVID-19 infection. Six percent of coronavirus deaths were caused by COVID-19 alone. Hydroxychloroquine is a miracle drug.

The “info-demic” that has accompanied the coronavirus disease pandemic has spread just as fast and insidiously as the virus itself, with misinformation, myths, and controversies running rampant in both the public sphere and among healthcare providers as well.

Watch our webinar, “Fact or Fiction? COVID-19 Myths and Controversies,” to get the facts directly from the experts.

Debunking 9 Common COVID-19 Myths

The COVID-19 pandemic has brought with it a so-called infodemic of misinformation and confusion among public and health care professionals about everything from how the virus is transmitted and who is susceptible to vaccine safety and miracle drugs. The MJH Life Sciences™ COVID-19 Coalition tackled some of the most common myths and controversies in the second in a biweekly series of webinars as part of a partnership with top health care thought leaders across a variety of medical disciplines.

Click here to download our whitepaper.

MJH

Battling Dual Threats: Flu and COVID-19 Converge

The convergence of coronavirus disease 2019 (COVID-19) and influenza this fall represents a pressing public health threat as hospital systems, clinicians, and the world’s population brace for the impact of dual epidemics.

What are the interactions between the seasonal influenza virus and SARS-CoV-2? How do we manage co-infections? How do we prioritize testing and diagnosis? What are some effective strategies for expanding vaccine coverage? What steps can be taken to cut transmission and preserve the capacity and function of health systems?

Watch our webinar event, “Battling Dual Threats: Flu and COVID-19 Converge,” featuring perspectives across virology and epidemiology.

Battling Dual Threats: Flu and COVID-19 Converge – 5 Takeaways

Health care professionals are bracing for new demands as the influenza season approaches, raising concerns about how a convergence of the annual illness with the coronavirus disease 2019 (COVID-19) pandemic might affect public health. The MJH Life Sciences™ COVID-19 Coalition, a partnership with top health care thought leaders across a variety of medical disciplines, offers resources to help navigate these challenges.

Click here to download our whitepaper.

MJH

COVID-19: Debating the Road Back to School

August traditionally kicks off “back-to-school” time in the United States, but this year presents new challenges as the coronavirus disease 2019 (COVID-19) pandemic continues to disrupt daily life. Still, school administrators, parents, and teachers are in the midst of trying to navigate school re-openings in a way that promotes learning, protects student safety, and prevents new infections.

Watch our webinar event featuring the biggest names in pediatrics and pharmacy as they discuss and debate current US Centers for Disease Control and Prevention guidance, outline what a safe return-to-school plan looks like, talk pros and cons of adding COVID-19 to the list of state-mandated immunizations for children once a vaccine is available, and share advice on how to counsel parents through this confusing time.

MJH

COVID-19: Debating the Road Back to School – Top 5 Takeaways

On a topic that is being debated in every town and city across the nation, our latest COVID-19 webinar hosted three healthcare experts as they debated what considerations factor into reopening decisions, which infection prevention measures need to be in place, how to maintain healthy school environments and more. To capture the most relevant insights from the event, we’ve developed a whitepaper highlighting the 5 key takeaways.

Click here to download our whitepaper.

MJH

COVID-19: Race for a Vaccine

Investigators and scientists around the globe are racing the clock to develop a vaccine to prevent SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19). With a handful of candidates entering phase 3 trials, huge investments from governments for the first 100 million doses, case counts continuously ticking upward, and policymakers working to untangle the logistical knots of distribution, the race for a COVID-19 vaccine is one of the most urgent public health challenges we’ve ever encountered.

Watch our webinar featuring the top minds in infectious disease, virology, and vaccinology to hear a breakdown of the top vaccine candidates, the latest from the ongoing clinical trials, and how to combat logistical hurdles associated with the rollout of a vaccine in the middle of a global pandemic.

CCOVID-19: Race for a Vaccine – Top 5 Takeaways

In a recent MJH Life Sciences webinar titled “COVID-19: Race for a Vaccine,” 3 experts weighed in on the process and challenges for developing the vaccine, as well as the hurdles that could stand in the way of fast, widespread deployment of a successful vaccine candidate. To capture the most relevant insights from the event, we’ve developed a whitepaper highlighting the 5 key takeaways.

Click here to download our whitepaper.





Updates


Pharmaceutical CEO Leadership: Collaboration in Pharma – Working Together


In this segment, members of the Pharmaceutical CEO Leadership: Collaboration in Pharma panel comment on the various types of collaboration within the industry. They also discuss how working with FDA helped streamline the drug development process through the pandemic and highlight additional lessons the industry could learn from collaborative efforts during COVID.

Pharmaceutical CEO Leadership: Collaboration in Pharma – Innovation


In this segment, members of the Pharmaceutical CEO Leadership: Collaboration in Pharma panel talk about the need to think outside the box when it comes to partnering, for example, by expanding relationships with technology, data science, and logistics companies. The challenges of protecting intellectual property are also discussed, as are the effects innovation can have on pricing and access.

Pharmaceutical CEO Leadership: Collaboration in Pharma – Choosing Partners


In this segment, members of the Pharmaceutical CEO Leadership: Collaboration in Pharma panel share what to look for in a collaborative partner and the benefit of entering into win-win situations. They also promote the potential of looking toward more unconventional types of partners and reveal what it takes to maintain successful relationships.

Pharmaceutical CEO Leadership: Collaboration in Pharma – Greater Good


In this segment, members of the Pharmaceutical CEO Leadership: Collaboration in Pharma panel present the impact of society at large on collaborations. Brought to the forefront during COVID, a sense of purpose drove many companies to join forces in novel ways, simply with the common goal of creating solutions. The challenge now is how to keep that momentum going.

Debunking 9 Common COVID-19 Myths

The COVID-19 pandemic has brought with it a so-called infodemic of misinformation and confusion among public and health care professionals about everything from how the virus is transmitted and who is susceptible to vaccine safety and miracle drugs. The MJH Life Sciences COVID-19 Coalition tackled some of the most common myths and controversies in the second in a biweekly series of webinars as part of a partnership with top health care thought leaders across a variety of medical disciplines.


Battling Dual Threats: Flu and COVID-19 Converge – 5 Takeaways

Health care professionals are bracing for new demands as the influenza season approaches, raising concerns about how a convergence of the annual illness with the coronavirus disease 2019 (COVID-19) pandemic might affect public health. The MJH Life Sciences COVID-19 Coalition, a partnership with top health care thought leaders across a variety of medical disciplines, offers resources to help navigate these challenges.


Pharmaceutical CEO Leadership: Valuing Employees


In this segment, members of the Pharmaceutical CEO Leadership Image of the Pharma Industry panel discuss the importance of showing employees that they are valued, especially during a pandemic, through increased support, communication, transparency, and trust.

Pharmaceutical CEO Leadership: Educating the Public


In this segment, members of the Pharmaceutical CEO Leadership Image of the Pharma Industry panel discuss how educating the general population about the value of pharma’s many life-changing therapies can provide a deeper understanding of and appreciation for what pharma does.

Pharmaceutical CEO Leadership: Connecting With Patients


In this segment, members of the Pharmaceutical CEO Leadership Image of the Pharma Industry panel discuss the importance of showing employees that they are valued, especially during a pandemic, through increased support, communication, transparency, and trust.

Pharmaceutical CEO Leadership: Industry Collaboration


In this segment, members of the Pharmaceutical CEO Leadership Image of the Pharma Industry panel discuss the benefits of collaboration, both internally and externally, to advance the greater mission of the pharma industry.

COVID-19: Debating the Road Back to School – Top 5 Takeaways

On a topic that is being debated in every town and city across the nation, our latest COVID-19 webinar hosted three healthcare experts as they debated what considerations factor into reopening decisions, which infection prevention measures need to be in place, how to maintain healthy school environments and more. To capture the most relevant insights from the event, we’ve developed a whitepaper highlighting the 5 key takeaways.


Practice management shifts to accommodate COVID-19

Over 1,100 physicians shared their experiences on changes in practice management as a result of COVID-19. The shifts in schedules, waiting room protocol and staff safety are priorities as we transition together to maintain safety and quality of care within the healthcare community.


COVID-19: Race for a Vaccine – Top 5 Takeaways

In a recent MJH Life Sciences webinar titled “COVID-19: Race for a Vaccine,” 3 experts weighed in on the process and challenges for developing the vaccine, as well as the hurdles that could stand in the way of fast, widespread deployment of a successful vaccine candidate. To capture the most relevant insights from the event, we’ve developed a whitepaper highlighting the 5 key takeaways.


The Effects of COVID-19 on the Office Visit

Over 1,000 physicians across multiple specialties weighed in on the effect COVID-19 has had on patient office visits, the volume, safety concerns and how healthcare staff are handling the new protocols. Our insightful findings will help in supporting the healthcare community, post pandemic.


COVID-19: Debating the Road Back to School

August traditionally kicks off “back-to-school” time in the United States, but this year presents new challenges as the coronavirus disease 2019 (COVID-19) pandemic continues to disrupt daily life. Still, school administrators, parents, and teachers are in the midst of trying to navigate school re-openings in a way that promotes learning, protects student safety, and prevents new infections.

Join MJH Life Sciences for a 1-hour live webinar event featuring the biggest names in pediatrics and pharmacy as they discuss and debate current US Centers for Disease Control and Prevention guidance, outline what a safe return-to-school plan looks like, talk pros and cons of adding COVID-19 to the list of state-mandated immunizations for children once a vaccine is available, and share advice on how to counsel parents through this confusing time.


MJH

COVID-19: Race for a Vaccine

Investigators and scientists around the globe are racing the clock to develop a vaccine to prevent SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19). With a handful of candidates entering phase 3 trials, huge investments from governments for the first 100 million doses, case counts continuously ticking upward, and policymakers working to untangle the logistical knots of distribution, the race for a COVID-19 vaccine is one of the most urgent public health challenges we’ve ever encountered.

Watch our webinar featuring the top minds in infectious disease, virology, and vaccinology to hear a breakdown of the top vaccine candidates, the latest from the ongoing clinical trials, and how to combat logistical hurdles associated with the rollout of a vaccine in the middle of a global pandemic.


MJH

COVID-19 is changing the way physicians communicate with their patients

Over 1,300 practitioners across multiple specialties shared their insights on patient communication post COVID-19. The results highlight trends and concerns to better understand the environment as we transition together to support the healthcare community.


The financial impact of COVID-19 on physician practices

Over 1,600 physicians weighed in on the financial effect of the pandemic and their thoughts on moving forward with the new protocols for post COVID-19 healthcare.


What About the Patients?

In this segment, members of the Pharmaceutical CEO Leadership During the Pandemic panel discuss the importance of supporting patients during the pandemic and re-opening to ensure they feel safe, are getting their prescriptions, are being diagnosed and have copay support.


Reaching Physicians

In this segment, members of the Pharmaceutical CEO Leadership During the Pandemic panel discuss their product launch and preparedness during the pandemic, as well it what it means to the future of reaching physicians.


Operational Leadership in the Time of COVID-19

In this segment, members of the Pharmaceutical CEO Leadership During the Pandemic panel discuss the first order of business when restrictions began to how they envision employee safety and operations in the future.


Our response to COVID-19

At MJH Life Sciences, our mission is to provide health care providers with the resources they need to enhance patient outcomes. To support clinicians during this uncertain time, we are continuing to develop timely, critical and accurate information for those on the front lines.

Please check out our schedule of webinars covering COVID-19 across all our brands.

If you’d like to read more about our response to this pandemic, please see the article below. And if you’d like to help those on the front lines, consider donating to the New Jersey Pandemic Relief Fund through this link. We’re matching April donations.

MJH Life Sciences Takes Innovative Charge During COVID-19 Health Crisis

By Rachel Narozniak, M.A.

Preventive measures aimed at flattening the curve of COVID-19 have altered standard patterns of information exchange in health care, and MJH Life Sciences™, the largest privately held, independent, full-service medical media company in North America, is innovatively adapting and expanding its educational offerings to ensure that health care professionals on the front lines have access to the resources they need during the COVID-19 pandemic.

“The majority of health care professionals are used to interacting with their peers, whether through the events that we host or national meetings. Over the past few weeks, we have seen meeting after meeting either postponed or canceled. The latter is where it becomes concerning because canceled meetings leave a big gap in the educational information that needs to be shared with clinicians,” said Mike Hennessy Jr., president and CEO of MJH Life Sciences.

Although information on the rapidly evolving COVID-19 pandemic is changing continuously, the commitment of MJH Life Sciences to the timely dissemination of credible clinical insights remains consistent. To equip health care professionals with the knowledge necessary to confront this health crisis and bridge the informational gaps associated with COVID-19, the company has expanded its portfolio of digital resources to include live webinars featuring leading disease specialists and other key opinion leaders.

During the week of March 23, MJH Life Sciences hosted seven different webinars, six of which were focused on COVID-19, said Hennessy. “We have programs in oncology, pharmacy, infectious disease and the veterinary and payer spaces. This past week alone, we educated more than 5,000 health care professionals, all from a virtual setting,” he noted, adding that the company will continue to coordinate webinars across health care specialties for the duration of the COVID-19 pandemic.

Of note, many of these webinars were organized in just a week to 10 days, according to MJH Life Sciences Vice Chairman Jack Lepping. “That is a testament to how our team is able to put together these events at a moment’s notice with an impressive group of renowned leaders,” he said. “We have to act quickly and be prepared for what’s coming down the pike tomorrow, all while maintaining quality and disseminating information in an extremely expedited fashion.”

The diversity of the company’s health care communication brands — such as OncLive®, the nation’s leading multimedia resource focused on providing oncology professionals with current and incisive information on patient care, and Contagion®, a prominent voice in the infectious disease space – allows MJH Life Sciences to “talk about the health crisis in the context of each health care specialty,” Lepping explained.

The company’s capacity to engage an array of clinical audiences across its broad network of brands, coupled with its ability to anticipate and meet informational needs via webinars and other digital offerings, positions MJH Life Sciences™ as a definitive leader in health care communications, one that is taking innovative charge at a critical time in medicine.

Furthermore, the company’s dedication to developing digital programs to deliver accurate and actionable insights to the health care community during the COVID-19 pandemic has not gone unnoticed, according to Silas Inman, senior vice president of content. Health care professionals have been “very receptive to these new formats,” he said. “We polled a group of clinicians at the end of one of our webinars and got an overwhelmingly positive return. Not only did they appreciate the webinar, but over 99% said they wanted more like it.”

The company’s vast menu of virtual offerings is but one part of its broader library of COVID-19 resources, Inman added. “In the past few months, we’ve developed more than 500 articles across brands covering the breadth of COVID-19, with close to 20 new articles added each day,” he said. “This content is providing useful information across multiple specialties on how to adjust day to day to the disease in the health care setting.”

Tailoring Web Content to the Times

Sustaining continuing medical education (CME) programming is a key focus of the MJH Life Sciences range of recent webcasts. Produced in partnership with the MJH Life Sciences brand Physicians’ Education Resource® (PER®) – a leading provider of live, online and print CME activities – and fellow MJH franchises Contagion®, Pharmacy Times Continuing Education (PTCE) and OncLive®, the self-funded webinars are free, delivering critical information to clinicians without a price barrier.

On March 25, Contagion® and PER® hosted “COVID-19 for Clinicians: What You Need to Know,” a live CME-certified webinar that drew a virtual audience of more than 1,300 attendees.

“Once the virus began spreading person to person, we moved quickly to secure the top names in infectious disease, all of whom went above and beyond to make time for Contagion® in between pressing commitments such as CNN interviews and calls with their respective governors,” said Alexandra Ward, M.A., the publication’s editorial director.


MJH

Invited speakers of the webinar included Helen W. Boucher, M.D., FACP, FIDSA, chief of the division of geographic medicine and infectious diseases at Tufts Medical Center; Carlos del Rio, M.D., director of clinical sciences and international research at the Emory Center for AIDS Research at the Emory University School of Medicine; Stanley Deresinski, M.D., clinical professor of medicine in the department of infectious diseases at Stanford University; and Jason C. Gallagher, Pharm.D., FCCP, FIDP, FIDSA, BCPS, Contagion® editor-in-chief and a clinical professor at Temple University’s School of Pharmacy.

“COVID-19 for Clinicians: What You Need to Know” is evidence that the core belief of MJH Life Sciences – that collaboration saves lives – has remained unchanged. “We are now simply collaborating virtually to save lives,” Ward said. “Being able to partner with PER® and provide CME for this event makes it all the more valuable to the clinicians we serve.”

The collaborative webcast was succeeded by a fellow live, CME-certified cooperation, “COVID-19 Essentials for Pharmacists and What You Need to Know Right Now,” hosted on March 28 and produced by PTCE and PER®. Expert panelists discussed the epidemiology of COVID-19 and current evidence on potential treatments and addressed COVID-19 questions frequently posed by patients and care providers alike.

The panel comprised Contagion®’s Gallagher as well as Daniel T. Abazia, Pharm.D., BCPS, CPPS, associate director of pharmacy at Capital Health, and Rupal Patel Mansukhani, Pharm.D., CTTS, FAPhA, a clinical associate professor at the Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey.

The CME-certified continuing webcast series “COVID-19 and Cancer Care: What Oncologists Need to Know Today” complemented these individual CME offerings. On March 23, the first installment of the OncLive® and PER® cooperative engaged more than 1,150 attendees, who tuned in to hear key opinion leaders in oncology discuss the risk of COVID-19 for patients with hematologic and solid tumor malignancies, optimal preventive protocols for cancer facilities across inpatient and outpatient settings, and therapeutic strategies.


MJH

Featured speakers included Amelia A. Langston, M.D., executive vice chair of the department of hematology and medical oncology at the Emory University School of Medicine, director of the bone marrow and stem cell transplant program at the Winship Cancer Institute of Emory University and medical director of the Winship Cancer Network; Ruben A. Mesa, M.D., FACP, director of The University of Texas Health San Antonio MD Anderson Cancer Center; Hope S. Rugo, M.D., FASCO, professor of medicine and director of Breast Oncology Clinical Trials Education at the University of California San Francisco, Helen Diller Family Comprehensive Cancer Center; and Cardinale Smith, M.D., Ph.D., an associate professor of medicine in the department of hematology and medical oncology and an associate professor of geriatrics and palliative medicine at the Icahn School of Medicine at Mount Sinai.

“Oncology has been a focal point for our company. Many of the thought leaders we work with reached out to us and asked that we take an active role here, and we were happy to do so,” said Hennessy. “We thought pulling together a large pool of top physicians to interact with community physicians was crucial at this time, and based on the overwhelming turnout that we saw in week one and the feedback that we received, we said, ‘This is something that we’re going to continue every week, at least until our audience feels that they have a good grasp of what they need to be doing.'”

Taking Conferences Digital

Beyond COVID-19-focused articles and webinars, the transition of various live events and conferences from an in-person to a digital format has been a driving force of innovation at MJH Life Sciences during the pandemic.

On March 12, New York Gov. Andrew Cuomo formally banned all public gatherings of more than 500 people. The new rule was established just one day before PER®‘s 13th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies conference was scheduled to take place at The Roosevelt Hotel in New York, New York. Beyond this statewide limitation, oncology institutions across the nation had also started to impose travel restrictions on clinicians.

However, MJH Life Sciences was already ahead of Cuomo’s announcement and the travel bans. “We made the decision 48 hours before Friday (March 13) to pivot and turn this into a virtual meeting, given the travel restrictions on faculty that we were hearing about,” said Ed Bosak, director of studio operations. “Our first action item was to specify the best interface for allowing the conference to appear as if it were planned to be completely virtual, even though 48 hours prior, it wasn’t.”


MJH From left: Daniel P. Petrylak, M.D. and Leonard G. Gomella, M.D., FACS, co-chair the 13th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies conference.

Bosak and fellow studio operations personnel worked around the clock to set up a studio in a boardroom at the MJH Life Sciences headquarters in Cranbury, New Jersey. From there, Bosak and his team drew upon the internal resources of the company’s in-house studio to facilitate the digital meeting. This included the green screen technology that studio operations regularly uses for panel filmings, such as the OncLive® Peer Exchange.

After establishing an infrastructure that would allow a live broadcast of the conference, MJH Life Sciences brought the program co-chairs – Leonard G. Gomella, M.D., FACS, director of the Sidney Kimmel Cancer Center Network of Thomas Jefferson University Hospital in Philadelphia, Pennsylvania, and Daniel P. Petrylak, M.D., co-leader of Cancer Signaling Networks at Yale Cancer Center in New Haven, Connecticut — to Cranbury to host the meeting as planned.


MJH

MJH From left: Daniel P. Petrylak, M.D. and Leonard G. Gomella, M.D., FACS, co-chair the 13th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies conference.

Streamed live on the PER® website, the 13th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies brought clinical evidence, pathologic insights and information on established and emergent treatment strategies alike to its viewers. Those uninhibited by COVID-19 institutional travel policies could still attend the event at The Roosevelt Hotel, view the broadcast from the venue and complete assessments to earn CME credit.

“It really exemplified our capacity to come together as a team to identify the most appropriate solutions, get the right troops on the ground and understand the intuitive software that the doctors needed to participate,” Bosak said. “We pride ourselves in our video innovation, and as we continue to innovate, our solutions will only get better.”

Lepping added, “Our ability to pull this off in two days was unprecedented.” The world-class studio at the MJH Life Sciences headquarters was key to the transition’s success. “Friends of mine in the business were amazed that we were able to do this and said they had tried to find studios to handle some of their canceled events, but the studios in New York were completely booked,” Lepping explained. “This gives you an idea of how important the studio was during this time.”

The dynamic approach of the MJH Life Sciences studio operations team to presenting the conference, amid challenges posed by COVID-19, extended to the 5th Annual School of Gastrointestinal Oncology® conference, broadcast live on March 21.

The company’s seamless, strategic transition of its live events to digital format is a product of its sustained focus on developing original video offerings, according to Hennessy. “We’ve always found video production to be extremely important, and it’s something that we started more than a decade ago, when it was probably a little ahead of its time in this space,” he said. “We will continue to push the envelope in terms of what we’re able to do from a video standpoint.”

As the COVID-19 pandemic evolves, so will the MJH Life Sciences collection of clinician-facing multimedia resources, allowing the company to fulfill its mission of delivering imperative insights to those who need them most, to inform practice and improve patient outcomes.

“Through these virtual events, webinars and articles, we’ve educated tens of thousands of clinicians. Each of these doctors, nurses and pharmacists is treating patients on the front line – they’re the real heroes of this pandemic,” said Inman. “One of our goals as a company is to improve patient care worldwide, and by arming these heroes with knowledge, we feel as if we’re fulfilling our mission in a highly meaningful way.”





California residents can request: "Do Not Sell My Personal information" by clicking here.